Al-Romaihi Hamad Eid, El-Khoury Rayane, Himatt Sayed, Derbala Moutaz F M, Idries Amjad Mohammed, Saeed Abid, Abdelmageed Maysa Kamal, Elawad Khalid Hamid, Alex Merin, Sallam Mohamed, Al-Shamali Maha Hammam, Coyle Peter, Alkaabi Saad, Chemaitelly Hiam, Bansal Devendra, Abu-Raddad Laith J
Department of Health Protection and Communicable Diseases Control, Ministry of Public Health, Doha, Qatar.
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, P.O. Box 24144, Doha, Qatar.
Sci Rep. 2025 Apr 18;15(1):13481. doi: 10.1038/s41598-025-96722-z.
Hepatitis C virus (HCV) infection poses a global health challenge, yet its epidemiology in Qatar remains underexplored. This study estimated HCV antibody (Ab) prevalence in Qatar and examined associated socio-demographic factors. From January 2017 to December 2019, the Ministry of Public Health conducted a national HCV awareness and surveillance campaign. A total of 81,615 individuals, including both Qatari nationals and expatriate residents from 137 countries, underwent HCV antibody testing using the Elecsys Anti-HCV II electrochemiluminescence immunoassay. Probability weights were applied to adjust for age, sex, and nationality, to the testing sample. Logistic regression assessed factors associated with HCV Ab positivity. Among individuals tested, 1149 were positive, 80,299 were negative, and 167 were indeterminate. The estimated HCV Ab prevalence in the study sample was 1.4% (95% CI 1.3-1.5%). The weighted HCV Ab prevalence in the resident population of Qatar was also estimated at 1.4% (95% CI 1.2-1.7%). HCV Ab positivity was strongly associated with age, with higher adjusted odds ratios (AORs) in older individuals. Disparities were noted among certain nationalities, with Bangladeshis and Tunisians having lower odds of infection, while Pakistanis, Egyptians, and Yemenis had higher odds of being infected. Males had a 1.97-fold (95% CI 1.47-2.65) higher odds of being HCV Ab positive compared to females. The considerable HCV Ab prevalence in Qatar underscores the need for targeted interventions, prevention and harm reduction strategies, and expanded testing and treatment programs to advance progress toward the 2030 elimination target.
丙型肝炎病毒(HCV)感染是一项全球性的健康挑战,但其在卡塔尔的流行病学情况仍未得到充分研究。本研究估算了卡塔尔丙型肝炎病毒抗体(Ab)的流行率,并考察了相关的社会人口学因素。2017年1月至2019年12月期间,公共卫生部开展了一项全国性的丙型肝炎病毒宣传与监测活动。共有81,615人接受了丙型肝炎病毒抗体检测,这些人包括卡塔尔国民以及来自137个国家的外籍居民,检测采用罗氏E170电化学发光免疫分析仪及配套试剂Elecsys Anti-HCV II进行丙型肝炎病毒抗体检测。采用概率权重对检测样本的年龄、性别和国籍进行调整。采用逻辑回归分析与丙型肝炎病毒抗体阳性相关的因素。在接受检测的个体中,1149人呈阳性,80,299人呈阴性,167人结果不确定。研究样本中估算的丙型肝炎病毒抗体流行率为1.4%(95%置信区间1.3 - 1.5%)。卡塔尔常住人口中加权后的丙型肝炎病毒抗体流行率估计也为1.4%(95%置信区间1.2 - 1.7%)。丙型肝炎病毒抗体阳性与年龄密切相关,年龄较大者的调整优势比(AOR)更高。在某些国籍人群中存在差异,孟加拉国人和突尼斯人感染几率较低,而巴基斯坦人、埃及人和也门人感染几率较高。男性丙型肝炎病毒抗体呈阳性的几率是女性的1.97倍(95%置信区间1.47 - 2.65)。卡塔尔相当高的丙型肝炎病毒抗体流行率凸显了采取针对性干预措施、预防和减少危害策略以及扩大检测和治疗项目的必要性,以推动在2030年实现消除目标方面取得进展。